Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.59 USD
−9.70 M USD
500.00 K USD
822.57 K
About Exicure, Inc.
Sector
Industry
CEO
Andy Yoo
Website
Headquarters
Chicago
Founded
2011
FIGI
BBG00GTJCSB4
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
$XCUR Next Target PTs .45-1.20-1.90 and higherExicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clini
Exicure (NASDAQ: $XCUR) Could Double Or More In Near-Term! 🎯Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clini
$XCUR Exicure Inc On Breakout watchlist
200ma break pre-market
downtrend is major resistance.
RSI & Momentum Bullish
targets as per chart
XCUR: Got Ways to Go $3.30 TargetFirst off, please don't take anything I been saying seriously or as financial advice. As always, this is on an opinion based basis. That being said XCUR has a reasonable target of reaching $3.30 soon in my opinion. It is still on a positive retracement wave looking at the entire chart history, and t
Exicure, Inc uptrend targets Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by
Exicure Inc. P-Modeling Pt Z. The Cajun Ship of ObliterationWelcome Hyperspace Archaeologists,
Come for the laughs, stay for the Art.
___________________
Find the "we are here" bubble.
I am most likely wrong...
Meh . Who cares.
but what... if..
good enough for me! All in. #pewpeww
__________________________________
Trade Taken:
Entry Range is $2.38 - $2.4
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of XCUR is 10.75 USD — it has decreased by −0.88% in the past 24 hours. Watch Exicure, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Exicure, Inc. stocks are traded under the ticker XCUR.
XCUR stock has fallen by −6.71% compared to the previous week, the month change is a −20.54% fall, over the last year Exicure, Inc. has showed a 314.26% increase.
XCUR reached its all-time high on Sep 18, 2018 with the price of 975.00 USD, and its all-time low was 1.44 USD and was reached on Sep 13, 2024. View more price dynamics on XCUR chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
XCUR stock is 6.91% volatile and has beta coefficient of 2.43. Track Exicure, Inc. stock price on the chart and check out the list of the most volatile stocks — is Exicure, Inc. there?
Today Exicure, Inc. has the market capitalization of 71.14 M, it has decreased by −27.12% over the last week.
Yes, you can track Exicure, Inc. financials in yearly and quarterly reports right on TradingView.
Exicure, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
XCUR net income for the last quarter is −7.18 M USD, while the quarter before that showed −1.09 M USD of net income which accounts for −558.20% change. Track more Exicure, Inc. financial stats to get the full picture.
No, XCUR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 7 employees. See our rating of the largest employees — is Exicure, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exicure, Inc. EBITDA is −4.13 M USD, and current EBITDA margin is −825.00%. See more stats in Exicure, Inc. financial statements.
Like other stocks, XCUR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exicure, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Exicure, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Exicure, Inc. stock shows the neutral signal. See more of Exicure, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.